Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | GALR1 | P47211 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617015 | 0.93 | TP53 (0.62) | TP53POLBHPGDGALR1CYP4F2 | |
| SCHEMBL4193217 | 0.91 | TP53 (0.61) | TP53POLBHPGDGALR1CYP4F2 | |
| SCHEMBL570920 | 0.90 | TDP1 (0.60) | HPGDTDP1L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL29360475 | 0.90 | TDP1 (0.60) | HPGDTDP1L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL4146997 | 0.89 | TDP1 (0.61) | TDP1L3MBTL1 | |
| SCHEMBL5863231 | 0.89 | TP53 (0.56) | TP53POLBHPGDGALR1CYP4F2 | |
| SCHEMBL2404818 | 0.88 | NPC1 (0.59) | TP53POLBHPGD | |
| Hydrochloric Acid SCHEMBL28864124 | 0.88 | L3MBTL1 (0.59) | HPGDTDP1L3MBTL1CYP4F2CYP4A11 | |
| Ammonia Solution, Strong SCHEMBL27753074 | 0.88 | TDP1 (0.59) | HPGDTDP1L3MBTL1CYP4F2CYP4A11 | |
| SCHEMBL11223090 | 0.86 | TP53 (0.59) | TP53POLBHPGDGALR1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | TP53 4633/4885POLB 4500/4885HPGD 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.